Topoisomerase I in Human Disease Pathogenesis and Treatments

Mammalian topoisomerase 1 (TOP1) is an essential enzyme for normal development. TOP1 relaxes supercoiled DNA to remove helical constraints that can otherwise hinder DNA replication and transcription and thus block cell growth. Unfortunately, this exact activity can covalently trap TOP1 on the DNA that could lead to cell death or mutagenesis, a precursor for tumorigenesis. It is therefore important for cells to find a proper balance between the utilization of the TOP1 catalytic activity to maintain DNA topology and the risk of accumulating the toxic DNA damages due to TOP1 trapping that prevents normal cell growth. In an apparent contradiction to the negative attribute of the TOP1 activity to genome stability, the detrimental effect of the TOP1-induced DNA lesions on cell survival has made this enzyme a prime target for cancer therapies to kill fast-growing cancer cells. In addition, cumulative evidence supports a direct role of TOP1 in promoting transcriptional progression independent of its topoisomerase activity. The involvement of TOP1 in transcriptional regulation has recently become a focus in developing potential new treatments for a subtype of autism spectrum disorders. Clearly, the impact of TOP1 on human health is multifold. In this review, we will summarize our current understandings on how TOP1 contributes to human diseases and how its activity is targeted for disease treatments.

[1]  S. Böhm,et al.  Chromatin Remodelling and RNA Processing , 2011 .

[2]  Tomio S. Takahashi,et al.  Topoisomerase 1 provokes the formation of short deletions in repeated sequences upon high transcription in Saccharomyces cerevisiae , 2010, Proceedings of the National Academy of Sciences.

[3]  H. Choy,et al.  Irinotecan and radiation in combined-modality therapy for solid tumors. , 2001, Oncology.

[4]  Michael C. Ryan,et al.  Transcription poisoning by Topoisomerase I is controlled by gene length, splice sites, and miR-142-3p. , 2013, Cancer research.

[5]  Yves Pommier,et al.  Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription , 2010, Nature Cell Biology.

[6]  Jian Jin,et al.  Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons , 2011, Nature.

[7]  H. Doyle,et al.  Post-translational protein modifications in antigen recognition and autoimmunity. , 2001, Trends in immunology.

[8]  Michihiko Fujii,et al.  Heterozygous disruption of the DNA topoisomerase I gene confers cellular resistance to camptothecin in human cells. , 2009, Biological & pharmaceutical bulletin.

[9]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[10]  Francesca Ferri,et al.  Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells. , 2006, Journal of molecular biology.

[11]  Andrés Aguilera,et al.  R loops: from transcription byproducts to threats to genome stability. , 2012, Molecular cell.

[12]  John T. Lis,et al.  Topoisomerase I interacts with transcribed regions in Drosophila cells , 1986, Cell.

[13]  J. Garst,et al.  Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer , 2007, Expert opinion on drug safety.

[14]  H. Phatnani,et al.  The phosphoCTD-interacting domain of Topoisomerase I. , 2010, Biochemical and biophysical research communications.

[15]  Yang Li,et al.  Aberrant Topoisomerase-1-DNA Lesions are Pathogenic in Neurodegenerative Genome Instability Syndromes , 2014, Nature Neuroscience.

[16]  Stormy J. Chamberlain,et al.  Topoisomerases facilitate transcription of long genes linked to autism , 2013, Nature.

[17]  W. Richard McCombie,et al.  Topoisomerase levels determine chemotherapy response in vitro and in vivo , 2008, Proceedings of the National Academy of Sciences.

[18]  Peter Tsang,et al.  R-loop formation at Snord116 mediates topotecan inhibition of Ube3a-antisense and allele-specific chromatin decondensation , 2013, Proceedings of the National Academy of Sciences.

[19]  Laura Baranello,et al.  Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: implications for physiological and therapeutic modulation of enzyme activity. , 2010, Biochimica et biophysica acta.

[20]  J. Tazi,et al.  Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I , 1996, Nature.

[21]  S. Morham,et al.  Targeted disruption of the mouse topoisomerase I gene by camptothecin selection , 1996, Molecular and cellular biology.

[22]  L. Chung,et al.  Antibodies in scleroderma: Direct pathogenicity and phenotypic associations , 2004, Current rheumatology reports.

[23]  Nils Brünner,et al.  Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development , 2013, Front. Oncol..

[24]  Yosef Shiloh,et al.  Ataxia-telangiectasia and the ATM gene: Linking neurodegeneration, immunodeficiency, and cancer to cell cycle checkpoints , 1996, Journal of Clinical Immunology.

[25]  Shervin Assassi,et al.  Decreased catalytic function with altered sumoylation of DNA topoisomerase I in the nuclei of scleroderma fibroblasts , 2011, Arthritis research & therapy.

[26]  Yves Pommier,et al.  Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA‐PK , 2009, The EMBO journal.

[27]  Rico N.P.M. Rinkel,et al.  Irinotecan-Induced Dysarthria , 2012, Case Reports in Oncology.

[28]  Yves Pommier,et al.  Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel , 2013, Molecular Cancer Therapeutics.

[29]  G. Reimer,et al.  An antigenic region of topoisomerase I in DNA polymerase chain reaction-generated fragments recognized by autoantibodies of scleroderma patients. , 1991, Molecular immunology.

[30]  Jerrold S. Levine,et al.  Apoptosis and autoimmunity , 1997, Current opinion in nephrology and hypertension.

[31]  Y. Pommier,et al.  Mutagenic Processing of Ribonucleotides in DNA by Yeast Topoisomerase I , 2011, Science.

[32]  Francesca Ferri,et al.  The effects of camptothecin on RNA polymerase II transcription: roles of DNA topoisomerase I. , 2007, Biochimie.

[33]  T Pawson,et al.  The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. , 1996, The EMBO journal.

[34]  J. Gui,et al.  Purification and characterization of a kinase specific for the serine- and arginine-rich pre-mRNA splicing factors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. O’Leary,et al.  Camptothecins: a review of their development and schedules of administration. , 1998, European journal of cancer.

[36]  T. Medsger,et al.  Molecular Recognition Patterns of Serum Anti-DNA Topoisomerase I Antibody in Systemic Sclerosis1 , 2004, The Journal of Immunology.

[37]  JAMES C. Wang,et al.  Cellular roles of DNA topoisomerases: a molecular perspective , 2002, Nature Reviews Molecular Cell Biology.

[38]  Suzanne L Wolden,et al.  Concurrent radiation with irinotecan and carboplatin in intermediate‐ and high‐risk rhabdomyosarcoma: A report on toxicity and efficacy from a prospective pilot phase II study , 2013, Pediatric blood & cancer.

[39]  A. Rands,et al.  Anti‐RNA polymerase antibodies in systemic sclerosis (SSc): association with anti‐topoisomerase I antibodies and identification of autoreactive subunits of RNA polymerase II , 1996, Clinical and experimental immunology.

[40]  Yilun Liu,et al.  RECQ5-dependent SUMOylation of DNA topoisomerase I prevents transcription-associated genome instability , 2015, Nature Communications.

[41]  J. Manley,et al.  Inactivation of the SR Protein Splicing Factor ASF/SF2 Results in Genomic Instability , 2005, Cell.

[42]  J. Lupski,et al.  Mutation of TDP1, encoding a topoisomerase I–dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy , 2002, Nature Genetics.

[43]  Michael Mahler,et al.  Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality? , 2010, Autoimmunity reviews.

[44]  Veronika Lang,et al.  Inhibition of sumoylation prevents experimental fibrosis , 2012, Annals of the rheumatic diseases.

[45]  Henk-Jan Guchelaar,et al.  Clinical and pharmacogenetic factors associated with irinotecan toxicity. , 2008, Cancer treatment reviews.